These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38734160)

  • 1. Comprehensive molecular characterization of long-term glioblastoma survivors.
    Xu H; Chen X; Sun Y; Hu X; Zhang X; Wang Y; Tang Q; Zhu Q; Song K; Chen H; Sheng X; Yao Y; Zhuang D; Chen L; Mao Y; Qin Z
    Cancer Lett; 2024 Jul; 593():216938. PubMed ID: 38734160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular profiling of long-term IDH-wildtype glioblastoma survivors.
    Burgenske DM; Yang J; Decker PA; Kollmeyer TM; Kosel ML; Mladek AC; Caron AA; Vaubel RA; Gupta SK; Kitange GJ; Sicotte H; Youland RS; Remonde D; Voss JS; Fritcher EGB; Kolsky KL; Ida CM; Meyer FB; Lachance DH; Parney IJ; Kipp BR; Giannini C; Sulman EP; Jenkins RB; Eckel-Passow JE; Sarkaria JN
    Neuro Oncol; 2019 Nov; 21(11):1458-1469. PubMed ID: 31346613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients.
    Amelot A; De Cremoux P; Quillien V; Polivka M; Adle-Biassette H; Lehmann-Che J; Françoise L; Carpentier AF; George B; Mandonnet E; Froelich S
    PLoS One; 2015; 10(7):e0130596. PubMed ID: 26158269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
    Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
    Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients.
    Mock A; Geisenberger C; Orlik C; Warta R; Schwager C; Jungk C; Dutruel C; Geiselhart L; Weichenhan D; Zucknick M; Nied AK; Friauf S; Exner J; Capper D; Hartmann C; Lahrmann B; Grabe N; Debus J; von Deimling A; Popanda O; Plass C; Unterberg A; Abdollahi A; Schmezer P; Herold-Mende C
    Int J Cancer; 2016 Jul; 139(2):424-32. PubMed ID: 26934681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methylation profiles of long- and short-term glioblastoma survivors.
    Shinawi T; Hill VK; Krex D; Schackert G; Gentle D; Morris MR; Wei W; Cruickshank G; Maher ER; Latif F
    Epigenetics; 2013 Feb; 8(2):149-56. PubMed ID: 23291739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological and molecular landscape of 5-year IDH-wild-type glioblastoma survivors: A multicentric retrospective study.
    Miele E; Anghileri E; Calatozzolo C; Lazzarini E; Patrizi S; Ciolfi A; Pedace L; Patanè M; Abballe L; Paterra R; Maddaloni L; Barresi S; Mastronuzzi A; Petruzzi A; Tramacere I; Farinotti M; Gurrieri L; Pirola E; Scarpelli M; Lombardi G; Villani V; Simonelli M; Merli R; Salmaggi A; Tartaglia M; Silvani A; DiMeco F; Calistri D; Lamperti E; Locatelli F; Indraccolo S; Pollo B
    Cancer Lett; 2024 Apr; 588():216711. PubMed ID: 38423245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated genomic analysis of survival outliers in glioblastoma.
    Peng S; Dhruv H; Armstrong B; Salhia B; Legendre C; Kiefer J; Parks J; Virk S; Sloan AE; Ostrom QT; Barnholtz-Sloan JS; Tran NL; Berens ME
    Neuro Oncol; 2017 Jun; 19(6):833-844. PubMed ID: 27932423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular features of glioblastomas in long-term survivors compared to short-term survivors-a matched-pair analysis.
    Sommerlath VN; Buergy D; Etminan N; Brehmer S; Reuss D; Sarria GR; Guiot MC; Hänggi D; Wenz F; Petrecca K; Giordano FA
    Radiat Oncol; 2022 Jan; 17(1):15. PubMed ID: 35073955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma.
    Jiang H; Yu K; Cui Y; Ren X; Li M; Zhang G; Yang C; Zhao X; Zhu Q; Lin S
    Front Oncol; 2021; 11():632663. PubMed ID: 34055603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival.
    Michaelsen SR; Urup T; Olsen LR; Broholm H; Lassen U; Poulsen HS
    J Neurooncol; 2018 May; 137(3):533-542. PubMed ID: 29305787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Factors Associated with Long-Term Survival in Patients with Glioblastoma.
    Madhugiri VS; Moiyadi AV; Shetty P; Gupta T; Epari S; Jalali R; Subeikshanan V; Dutt A; Sasidharan GM; Roopesh Kumar VR; Shankar Ganesh CV; Ramesh AS; Sathia Prabhu A
    World Neurosurg; 2021 May; 149():e758-e765. PubMed ID: 33540096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term survival in patients with IDH-wildtype glioblastoma: clinical and molecular characteristics.
    Chehade G; Lawson TM; Lelotte J; Daoud L; Di Perri D; Whenham N; Duprez T; Tajeddine N; Tissir F; Raftopoulos C
    Acta Neurochir (Wien); 2023 Apr; 165(4):1075-1085. PubMed ID: 36920664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional diversity of long-term glioblastoma survivors.
    Gerber NK; Goenka A; Turcan S; Reyngold M; Makarov V; Kannan K; Beal K; Omuro A; Yamada Y; Gutin P; Brennan CW; Huse JT; Chan TA
    Neuro Oncol; 2014 Sep; 16(9):1186-95. PubMed ID: 24662514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Predictors of Long-Term Survival in Glioblastoma Multiforme Patients.
    Lu J; Cowperthwaite MC; Burnett MG; Shpak M
    PLoS One; 2016; 11(4):e0154313. PubMed ID: 27124395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in methylation profiles between long-term survivors and short-term survivors of IDH-wild-type glioblastoma.
    van der Meulen M; Ramos RC; Voisin MR; Patil V; Wei Q; Singh O; Climans SA; Kalidindi N; Or R; Aldape K; Diamandis P; Munoz DG; Zadeh G; Mason WP
    Neurooncol Adv; 2024; 6(1):vdae001. PubMed ID: 38312227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification.
    Wenger A; Ferreyra Vega S; Kling T; Bontell TO; Jakola AS; Carén H
    Neuro Oncol; 2019 May; 21(5):616-627. PubMed ID: 30668814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of deeply phenotyped GBM cohorts of 'short-term' and 'long-term' survivors.
    Biswas A; Salvucci M; Connor K; Düssmann H; Carberry S; Fichtner M; King E; Murphy B; O'Farrell AC; Cryan J; Beausang A; Heffernan J; Cremona M; Hennessy BT; Clerkin J; Sweeney KJ; MacNally S; Brett F; O'Halloran P; Bacon O; Furney S; Verreault M; Quissac E; Bielle F; Ahmed MH; Idbaih A; Leenstra S; Ntafoulis I; Fabro F; Lamfers M; Golebiewska A; Hertel F; Niclou SP; Yen RTC; Kremer A; Dilcan G; Lodi F; Arijs I; Lambrechts D; Purushothama MK; Kel A; Byrne AT; Prehn JHM
    J Neurooncol; 2023 Jun; 163(2):327-338. PubMed ID: 37237151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
    Kessler T; Sahm F; Sadik A; Stichel D; Hertenstein A; Reifenberger G; Zacher A; Sabel M; Tabatabai G; Steinbach J; Sure U; Krex D; Grosu AL; Bewerunge-Hudler M; Jones D; Pfister SM; Weller M; Opitz C; Bendszus M; von Deimling A; Platten M; Wick W
    Neuro Oncol; 2018 Feb; 20(3):367-379. PubMed ID: 29016808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrative analysis of DNA methylation suggests down-regulation of oncogenic pathways and reduced somatic mutation rates in survival outliers of glioblastoma.
    Hwang T; Mathios D; McDonald KL; Daris I; Park SH; Burger PC; Kim S; Dho YS; Carolyn H; Bettegowda C; Shin JH; Lim M; Park CK
    Acta Neuropathol Commun; 2019 Jun; 7(1):88. PubMed ID: 31159876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.